Next-generation medicine: Combining BCR-ABL and hedgehog-targeted therapies

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Disease relapse remains a major cause of death in patients with BCR-ABL-positive leukemia despite advances in treatment with kinase inhibitors. Significant efforts are underway to target pathways that maintain leukemia stem cells. Targeting these pathways holds promise for definitive leukemia eradication or improvement of the effectiveness of currently available therapies.

Original languageEnglish (US)
Pages (from-to)1309-1311
Number of pages3
JournalClinical Cancer Research
Volume19
Issue number6
DOIs
StatePublished - Mar 15 2013

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this